Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Adenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma

Authors: Ran-yi Liu, Ying-hui Zhu, Ling Zhou, Peng Zhao, Hong-li Li, Lan-cai Zhu, Hong-yu Han, Huan-xin Lin, Liang Kang, Jiang-xue Wu, Wenlin Huang

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

Interferon-γ (IFN-γ) is regarded as a potent antitumor agent, but its clinical application is limited by its short half-life and significant side effects. In this paper, we tried to develop IFN-γ gene therapy by a replication defective adenovirus encoding the human IFN-γ (Ad-IFNγ), and evaluate the antitumoral effects of Ad-IFNγ on nasopharyngeal carcinoma (NPC) cell lines in vitro and in xenografts model.

Methods

The mRNA levels of human IFN-γ in Ad-IFNγ-infected NPC cells were detected by reverse transcription-polymerase chain reaction (RT-PCR), and IFN-γ protein concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in the culture supernatants of NPC cells and tumor tissues and bloods of nude mice treated with Ad-IFNγ. The effects of Ad-IFNγ on NPC cell proliferation was determined using MTT assay, cell cycle distribution was determined by flow cytometry analysis for DNA content, and cells apoptosis were analyzed by Annexin V-FITC/7-AAD binding assay and hoechst 33342/PI double staining. The anti-tumor effects and toxicity of Ad-IFNγ were evaluated in BALB/c nude mice carrying NPC xenografts.

Results

The results demonstrated that Ad-IFNγ efficiently expressed human IFN-γ protein in NPC cell lines in vitro and in vivo. Ad-IFNγ infection resulted in antiproliferative effects on NPC cells by inducing G1 phase arrest and cell apoptosis. Intratumoral administration of Ad-IFNγ significantly inhibited the growth of CNE-2 and C666-1 cell xenografts in nude mice, while no significant toxicity was observed.

Conclusions

These findings indicate IFN-γ gene therapy mediated by replication defective adenoviral vector is likely a promising approach in the treatment of nasopharyngeal carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM: Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012, 31: 185-196.CrossRefPubMedPubMedCentral Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM: Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012, 31: 185-196.CrossRefPubMedPubMedCentral
2.
go back to reference Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C: Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009, 74: 1070-1076. 10.1016/j.ijrobp.2008.09.008.CrossRefPubMed Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C: Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009, 74: 1070-1076. 10.1016/j.ijrobp.2008.09.008.CrossRefPubMed
4.
go back to reference Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.CrossRefPubMed Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.CrossRefPubMed
5.
go back to reference Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004, 75: 163-189.CrossRefPubMed Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004, 75: 163-189.CrossRefPubMed
6.
go back to reference Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM: Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res. 2000, 60: 3904-3908.PubMed Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM: Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res. 2000, 60: 3904-3908.PubMed
7.
go back to reference Sasagawa T, Hlaing M, Akaike T: Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. Biochem Biophys Res Commun. 2000, 272: 674-680. 10.1006/bbrc.2000.2835.CrossRefPubMed Sasagawa T, Hlaing M, Akaike T: Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. Biochem Biophys Res Commun. 2000, 272: 674-680. 10.1006/bbrc.2000.2835.CrossRefPubMed
8.
go back to reference Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S: Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001, 49: 251-262. 10.1136/gut.49.2.251.CrossRefPubMedPubMedCentral Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S: Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001, 49: 251-262. 10.1136/gut.49.2.251.CrossRefPubMedPubMedCentral
9.
go back to reference Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W: Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res. 2006, 12: 4702-4713. 10.1158/1078-0432.CCR-06-0520.CrossRefPubMed Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W: Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res. 2006, 12: 4702-4713. 10.1158/1078-0432.CCR-06-0520.CrossRefPubMed
10.
go back to reference Zhao P, Zhu YH, Wu JX, Liu RY, Zhu XY, Xiao X, Li HL, Huang BJ, Xie FJ, Chen JM: Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth. Life Sci. 2007, 81: 695-701. 10.1016/j.lfs.2007.05.028.CrossRefPubMed Zhao P, Zhu YH, Wu JX, Liu RY, Zhu XY, Xiao X, Li HL, Huang BJ, Xie FJ, Chen JM: Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth. Life Sci. 2007, 81: 695-701. 10.1016/j.lfs.2007.05.028.CrossRefPubMed
11.
go back to reference Kane A, Yang I: Interferon-gamma in brain tumor immunotherapy. Neurosurg Clin N Am. 2010, 21: 77-86. 10.1016/j.nec.2009.08.011.CrossRefPubMed Kane A, Yang I: Interferon-gamma in brain tumor immunotherapy. Neurosurg Clin N Am. 2010, 21: 77-86. 10.1016/j.nec.2009.08.011.CrossRefPubMed
12.
go back to reference Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000, 82: 1138-1144.CrossRefPubMedPubMedCentral Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000, 82: 1138-1144.CrossRefPubMedPubMedCentral
13.
go back to reference Hastie C: Interferon gamma, a possible therapeutic approach for late-stage prostate cancer?. Anticancer Res. 2008, 28: 2843-2849.PubMed Hastie C: Interferon gamma, a possible therapeutic approach for late-stage prostate cancer?. Anticancer Res. 2008, 28: 2843-2849.PubMed
14.
go back to reference Miller CH, Maher SG, Young HA: Clinical use of Interferon-gamma. Ann N Y Acad Sci. 2009, 1182: 69-79. 10.1111/j.1749-6632.2009.05069.x.CrossRefPubMed Miller CH, Maher SG, Young HA: Clinical use of Interferon-gamma. Ann N Y Acad Sci. 2009, 1182: 69-79. 10.1111/j.1749-6632.2009.05069.x.CrossRefPubMed
15.
go back to reference Dummer R, Eichmuller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A: Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010, 18: 1244-1247. 10.1038/mt.2010.52.CrossRefPubMedPubMedCentral Dummer R, Eichmuller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A: Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010, 18: 1244-1247. 10.1038/mt.2010.52.CrossRefPubMedPubMedCentral
16.
go back to reference Wu J, Xiao X, Jia H, Chen J, Zhu Y, Zhao P, Lin H, Huang W: Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer. 2009, 9: 55-10.1186/1471-2407-9-55.CrossRefPubMedPubMedCentral Wu J, Xiao X, Jia H, Chen J, Zhu Y, Zhao P, Lin H, Huang W: Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer. 2009, 9: 55-10.1186/1471-2407-9-55.CrossRefPubMedPubMedCentral
17.
go back to reference Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK: Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene. 2011, 30: 4814-4823. 10.1038/onc.2011.189.CrossRefPubMedPubMedCentral Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK: Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene. 2011, 30: 4814-4823. 10.1038/onc.2011.189.CrossRefPubMedPubMedCentral
18.
go back to reference O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997, 88: 277-285. 10.1016/S0092-8674(00)81848-6.CrossRefPubMed O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997, 88: 277-285. 10.1016/S0092-8674(00)81848-6.CrossRefPubMed
19.
go back to reference Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, Zeng YX, Huang W: Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer. 2006, 118: 2064-2071. 10.1002/ijc.21585.CrossRefPubMed Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, Zeng YX, Huang W: Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer. 2006, 118: 2064-2071. 10.1002/ijc.21585.CrossRefPubMed
20.
go back to reference Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13: 95-109. 10.1016/S1359-6101(01)00038-7.CrossRefPubMed Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13: 95-109. 10.1016/S1359-6101(01)00038-7.CrossRefPubMed
21.
go back to reference Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD: Interferon-gamma and cancer immunoediting. Immunol Res. 2005, 32: 231-245. 10.1385/IR:32:1-3:231.CrossRefPubMed Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD: Interferon-gamma and cancer immunoediting. Immunol Res. 2005, 32: 231-245. 10.1385/IR:32:1-3:231.CrossRefPubMed
22.
go back to reference Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A: Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005, 65: 2906-2913. 10.1158/0008-5472.CAN-04-4282.CrossRefPubMed Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A: Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005, 65: 2906-2913. 10.1158/0008-5472.CAN-04-4282.CrossRefPubMed
23.
go back to reference Gattacceca F, Pilatte Y, Billard C, Monnet I, Moritz S, Le Carrou J, Eloit M, Jaurand MC: Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res. 2002, 8: 3298-3304.PubMed Gattacceca F, Pilatte Y, Billard C, Monnet I, Moritz S, Le Carrou J, Eloit M, Jaurand MC: Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res. 2002, 8: 3298-3304.PubMed
24.
go back to reference Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P: Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood. 2004, 104: 1631-1638. 10.1182/blood-2004-01-0360.CrossRefPubMed Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P: Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood. 2004, 104: 1631-1638. 10.1182/blood-2004-01-0360.CrossRefPubMed
25.
go back to reference Sangfelt O, Erickson S, Grander D: Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000, 5: D479-D487. 10.2741/Sangfelt.CrossRefPubMed Sangfelt O, Erickson S, Grander D: Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000, 5: D479-D487. 10.2741/Sangfelt.CrossRefPubMed
26.
go back to reference Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC: Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003, 8: 237-249. 10.1023/A:1023668705040.CrossRefPubMed Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC: Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003, 8: 237-249. 10.1023/A:1023668705040.CrossRefPubMed
27.
go back to reference Gollob JA, Sciambi CJ, Huang Z, Dressman HK: Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res. 2005, 65: 8869-8877. 10.1158/0008-5472.CAN-05-1387.CrossRefPubMed Gollob JA, Sciambi CJ, Huang Z, Dressman HK: Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res. 2005, 65: 8869-8877. 10.1158/0008-5472.CAN-05-1387.CrossRefPubMed
28.
go back to reference Wall L, Burke F, Barton C, Smyth J, Balkwill F: IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res. 2003, 9: 2487-2496.PubMed Wall L, Burke F, Barton C, Smyth J, Balkwill F: IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res. 2003, 9: 2487-2496.PubMed
29.
go back to reference Dunn GP, Sheehan KC, Old LJ, Schreiber RD: IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65: 3447-3453.PubMed Dunn GP, Sheehan KC, Old LJ, Schreiber RD: IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65: 3447-3453.PubMed
31.
go back to reference Ruiz-Ruiz C, de Almodovar Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A: The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem. 2004, 279: 19712-19720. 10.1074/jbc.M313023200.CrossRefPubMed Ruiz-Ruiz C, de Almodovar Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A: The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem. 2004, 279: 19712-19720. 10.1074/jbc.M313023200.CrossRefPubMed
32.
go back to reference Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, Dong M, Hyodoh F, Yata K, Wada H: TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res. 2006, 26: 4115-4124.PubMed Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, Dong M, Hyodoh F, Yata K, Wada H: TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res. 2006, 26: 4115-4124.PubMed
33.
go back to reference Barton C, Davies D, Balkwill F, Burke F: Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer. 2005, 41: 1474-1486. 10.1016/j.ejca.2005.03.022.CrossRefPubMed Barton C, Davies D, Balkwill F, Burke F: Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer. 2005, 41: 1474-1486. 10.1016/j.ejca.2005.03.022.CrossRefPubMed
34.
go back to reference Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A: IP-10 induces dissociation of newly formed blood vessels. J Cell Sci. 2009, 122: 2064-2077. 10.1242/jcs.048793.CrossRefPubMedPubMedCentral Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A: IP-10 induces dissociation of newly formed blood vessels. J Cell Sci. 2009, 122: 2064-2077. 10.1242/jcs.048793.CrossRefPubMedPubMedCentral
35.
go back to reference Bodnar RJ, Yates CC, Wells A: IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006, 98: 617-625. 10.1161/01.RES.0000209968.66606.10.CrossRefPubMed Bodnar RJ, Yates CC, Wells A: IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006, 98: 617-625. 10.1161/01.RES.0000209968.66606.10.CrossRefPubMed
36.
go back to reference Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002, 86: 768-773. 10.1038/sj.bjc.6600152.CrossRefPubMedPubMedCentral Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002, 86: 768-773. 10.1038/sj.bjc.6600152.CrossRefPubMedPubMedCentral
37.
go back to reference Lu Y, Yang W, Qin C, Zhang L, Deng J, Liu S, Qin Z: Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol. 2009, 183: 6413-6421. 10.4049/jimmunol.0901073.CrossRefPubMed Lu Y, Yang W, Qin C, Zhang L, Deng J, Liu S, Qin Z: Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol. 2009, 183: 6413-6421. 10.4049/jimmunol.0901073.CrossRefPubMed
38.
go back to reference Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ: IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun. 2008, 374: 479-484. 10.1016/j.bbrc.2008.07.042.CrossRefPubMedPubMedCentral Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ: IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun. 2008, 374: 479-484. 10.1016/j.bbrc.2008.07.042.CrossRefPubMedPubMedCentral
39.
go back to reference Sharma B, Iozzo RV: Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem. 1998, 273: 4642-4646. 10.1074/jbc.273.8.4642.CrossRefPubMed Sharma B, Iozzo RV: Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem. 1998, 273: 4642-4646. 10.1074/jbc.273.8.4642.CrossRefPubMed
40.
go back to reference Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther. 2000, 11: 247-261. 10.1089/10430340050015996.CrossRefPubMed Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther. 2000, 11: 247-261. 10.1089/10430340050015996.CrossRefPubMed
41.
go back to reference Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993, 11: 571-611. 10.1146/annurev.iy.11.040193.003035.CrossRefPubMed Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993, 11: 571-611. 10.1146/annurev.iy.11.040193.003035.CrossRefPubMed
42.
go back to reference Zhang F, Lu W, Dong Z: Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res. 2002, 8: 2942-2951.PubMed Zhang F, Lu W, Dong Z: Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res. 2002, 8: 2942-2951.PubMed
43.
go back to reference Nielsen LL: NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model. Oncol Rep. 2000, 7: 151-155.PubMed Nielsen LL: NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model. Oncol Rep. 2000, 7: 151-155.PubMed
44.
go back to reference Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB: Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res. 2005, 65: 9056-9063. 10.1158/0008-5472.CAN-05-1261.CrossRefPubMed Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB: Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res. 2005, 65: 9056-9063. 10.1158/0008-5472.CAN-05-1261.CrossRefPubMed
45.
go back to reference Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA: Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A. 1984, 81: 886-888. 10.1073/pnas.81.3.886.CrossRefPubMedPubMedCentral Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA: Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A. 1984, 81: 886-888. 10.1073/pnas.81.3.886.CrossRefPubMedPubMedCentral
46.
go back to reference Seliger B, Ruiz-Cabello F, Garrido F: IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res. 2008, 101: 249-276.CrossRefPubMed Seliger B, Ruiz-Cabello F, Garrido F: IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res. 2008, 101: 249-276.CrossRefPubMed
47.
go back to reference Hu X, Chakravarty SD, Ivashkiv LB: Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev. 2008, 226: 41-56. 10.1111/j.1600-065X.2008.00707.x.CrossRefPubMedPubMedCentral Hu X, Chakravarty SD, Ivashkiv LB: Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev. 2008, 226: 41-56. 10.1111/j.1600-065X.2008.00707.x.CrossRefPubMedPubMedCentral
48.
go back to reference Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011, 331: 1565-1570. 10.1126/science.1203486.CrossRefPubMed Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011, 331: 1565-1570. 10.1126/science.1203486.CrossRefPubMed
Metadata
Title
Adenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma
Authors
Ran-yi Liu
Ying-hui Zhu
Ling Zhou
Peng Zhao
Hong-li Li
Lan-cai Zhu
Hong-yu Han
Huan-xin Lin
Liang Kang
Jiang-xue Wu
Wenlin Huang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-256

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.